Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Work In Process: 2024-2025

  • Day One Biopharmaceuticals' Work In Process was N/A to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2024, which is N/A change from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Work In Process stood at $6.0 million for Q3 2025, which was up 16.53% from $5.2 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Work In Process high stood at $6.0 million for Q3 2025, and its period low was $2.4 million during Q4 2024.
  • In the last 2 years, Day One Biopharmaceuticals' Work In Process had a median value of $5.2 million in 2025 and averaged $4.5 million.